Alexandria Real Estate Equities ARE

$41.50 -2.32 (-5.29%)

Valuation

Market cap
7,635,548,000
Revenue TTM
$3,026,560,000
Net income TTM
$-1,429,570,000
PE ratio
5.63
Forward PE
6.90
Profit margin
-47.23%
Debt to equity
0.67

Trading

Volume
2,853,300
Avg volume
2,001,700
Day's range
$41.34 – $43.68
Shares out
174,248,000
Stochastic %K
2%
Beta
1.16
Analysts
Hold
Price target
$52.13

Price

Company profile

Alexandria Real Estate Equities, Inc., an S&P 500 company, is a best-in-class, mission-driven life science REIT making a positive and lasting impact on the world. With our founding in 1994, Alexandria pioneered the life science real estate niche. Alexandria is the preeminent and longest-tenured owner, operator, and developer of collaborative Megacampus™ ecosystems in AAA life science and advanced technology innovatio...

Show more

Alexandria Real Estate Equities, Inc., an S&P 500 company, is a best-in-class, mission-driven life science REIT making a positive and lasting impact on the world. With our founding in 1994, Alexandria pioneered the life science real estate niche. Alexandria is the preeminent and longest-tenured owner, operator, and developer of collaborative Megacampus™ ecosystems in AAA life science and advanced technology innovation cluster locations, including Greater Boston, San Diego, the San Francisco Bay Area, Seattle, Maryland, Research Triangle, and New York City. Alexandria Real Estate Equities, Inc. was established in 1994 and was incorporated in Maryland.

Industry
REIT - Office
Sector
Real Estate
Phone
626 578 0777
Website
https://www.are.com
Address
26 North Euclid Avenue, Pasadena, United States

Latest news

Stocktwits

qqqweeklies Oct 15, 1:38 AM
$ARE sad
0 replies
Koapark Oct 14, 9:10 PM
$ARE What’s amazing is that there are like 5 or 6 people on this board that give a shit about this company. Probably the best value for a quality REIT out there right now. Not complaining, thrilled to be able to continually add at these prices
1 replies
ThomasTrainTrader Oct 14, 8:30 PM
$ARE if they buy back $500 million worth of shares at the current price, they would be also alleviating about $35 millon of an annual dividends. Since their borrow rate is 5% they would actually be netting +$10 million or so a year. Honestly not a bad way to spend the huge amount of credit ($5 billion) that they have secured. On top of all of that they also reclaim a substantial part of the ownership of the company that they can later resell at a much higher value
0 replies
StockFactz Oct 14, 8:20 PM
$ARE Pitiful one of the most important biotech landlords with the most advanced lab spaces is getting destroyed like this. Fun fact, $ARE's entire market cap is only worth about 3 days of the countries defense budget (not counting expenses outside the allocation act which is substantially more). Is biotechnology not an important pillar of national security? Is it also not important for the wellbeing and flourishing of the citizens of this country?
1 replies
StockFactz Oct 14, 7:32 PM
$ARE I honestly beg anyone to present an argument as to why the price to FFO ratio right now should not at least 9x. 6.4x is basically assuming the company is completely done for. $DEI is trading at a 6.6x P/FFO ratio, and their portfolio is struggling conventional office REITs with a 75% occupancy rate. Is the market really that retarded or as I've seen described REIT-arded
1 replies
ThomasTrainTrader Oct 14, 7:26 PM
$ARE I doubt that they’re gonna do buybacks but they really should… $500 million that is set aside. Especially after dispositions they should have a ton of capital. Right now they’re buying it like probably a 30 to 40% discount, they can then sell that stock again later to raise funds if needed. Just don’t know if they’re willing to make that kind of pragmatic decision right now in order to trade-off some of their flexibility
0 replies
StockFactz Oct 14, 7:21 PM
$ARE Analysts should have already known about the declining growth of biotech in the sense that that it couldn't continue infinitely expanding at the rate it did in 2021. and they were kind of idiots to think otherwise. The 10-year historical average of price to FFO is 18.4x, in 2021 it was 24.2x, in 2024, it was 12.4x which was already about 30% lower than average. Right now we're sitting at about 6.4x which is half of what it was in 2024. I think to any reasonable analyst, which is quite hard to find nowadays, they would honestly I can continuously project a fair price to FFO range even with the current headwinds at around 9 to 12x.
0 replies
StockFactz Oct 14, 7:05 PM
$ARE You would think this company is on the verge of collapse since it's being valued at less than 45% of it's net asset value but actually it is one of the strongest positioned biotech REITs not to mention office REITs in the world. Not an exaggeration to say they may own the most advanced lab spaces in the western hemisphere with only China possibly rivaling them on a global scale. ~87% occupancy rate -$2.9 billion in dispositions planned - Secured credit line and fortified balance sheet puts its operations runway literal leagues above any of its competitors
0 replies